Growth rate-corrected (GR) dose-response metrics across a panel of 71 breast cancer cell lines treated with a library of small molecule and antibody perturbagens. Dataset 1 of 4: Relative cell counts and normalized growth rate inhibition values across technical replicates. - Dataset (ID:20268)
Download: Excel (XLSX), Comma-separated (CSV)
| Cell | Clinical Subtype | Transcriptional Subtype | Small Molecule | Antibody | Perturbagen Target | Perturbagen Class | Perturbagen Concentration | Perturbagen Conc Unit | Biological Replicate ID | Relative Cell Count | Normalized Growth Rate Inhibition Value | Nominal Division Rate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| MDA-MB-468 | TNBC | Basal A | Cetuximab | EGFR | ErbB | 0.00000877 | uM | 7906.018 | 0.6874 | 0.3239 | 0.9087 | |
| MDA-MB-468 | TNBC | Basal A | Cetuximab | EGFR | ErbB | 0.0000438 | uM | 7906.018 | 0.5829 | 0.1043 | 0.9087 | |
| MDA-MB-468 | TNBC | Basal A | Cetuximab | EGFR | ErbB | 0.000219 | uM | 7906.018 | 0.7672 | 0.4940 | 0.9087 | |
| MDA-MB-468 | TNBC | Basal A | Cetuximab | EGFR | ErbB | 0.0011 | uM | 7906.018 | 0.8728 | 0.7219 | 0.9087 | |
| MDA-MB-468 | TNBC | Basal A | Cetuximab | EGFR | ErbB | 0.00548 | uM | 7906.018 | 0.7521 | 0.4618 | 0.9087 | |
| MDA-MB-468 | TNBC | Basal A | Cetuximab | EGFR | ErbB | 0.0274 | uM | 7906.018 | 1.0422 | 1.0930 | 0.9087 | |
| MDA-MB-468 | TNBC | Basal A | Cetuximab | EGFR | ErbB | 0.137 | uM | 7906.018 | 1.0025 | 1.0056 | 0.9087 | |
| MDA-MB-468 | TNBC | Basal A | Cetuximab | EGFR | ErbB | 0.685 | uM | 7906.018 | 0.7780 | 0.5173 | 0.9087 | |
| MDA-MB-468 | TNBC | Basal A | Cetuximab | EGFR | ErbB | 0.00000175 | uM | 7907.018 | 0.8446 | 0.7898 | 1.5217 | |
| MDA-MB-468 | TNBC | Basal A | Cetuximab | EGFR | ErbB | 0.00000877 | uM | 7907.018 | 1.1042 | 1.1346 | 1.5217 | |
| MDA-MB-468 | TNBC | Basal A | Cetuximab | EGFR | ErbB | 0.0000438 | uM | 7907.018 | 0.9037 | 0.8713 | 1.5217 | |
| MDA-MB-468 | TNBC | Basal A | Cetuximab | EGFR | ErbB | 0.000219 | uM | 7907.018 | 0.9953 | 0.9939 | 1.5217 | |
| MDA-MB-468 | TNBC | Basal A | Cetuximab | EGFR | ErbB | 0.0011 | uM | 7907.018 | 1.0328 | 1.0428 | 1.5217 | |
| MDA-MB-468 | TNBC | Basal A | Cetuximab | EGFR | ErbB | 0.00548 | uM | 7907.018 | 0.9599 | 0.9469 | 1.5217 | |
| MDA-MB-468 | TNBC | Basal A | Cetuximab | EGFR | ErbB | 0.0274 | uM | 7907.018 | 0.8972 | 0.8624 | 1.5217 | |
| MDA-MB-468 | TNBC | Basal A | Cetuximab | EGFR | ErbB | 0.137 | uM | 7907.018 | 1.0589 | 1.0767 | 1.5217 | |
| MDA-MB-468 | TNBC | Basal A | Cetuximab | EGFR | ErbB | 0.685 | uM | 7907.018 | 0.7772 | 0.6947 | 1.5217 | |
| SK-BR-3 | HER2amp | Luminal | Cetuximab | EGFR | ErbB | 0.00000175 | uM | 7912.018 | 0.9863 | 0.9622 | 0.7203 | |
| SK-BR-3 | HER2amp | Luminal | Cetuximab | EGFR | ErbB | 0.00000877 | uM | 7912.018 | 1.0557 | 1.1562 | 0.7203 | |
| SK-BR-3 | HER2amp | Luminal | Cetuximab | EGFR | ErbB | 0.0000438 | uM | 7912.018 | 0.8690 | 0.6458 | 0.7203 | |
| SK-BR-3 | HER2amp | Luminal | Cetuximab | EGFR | ErbB | 0.000219 | uM | 7912.018 | 0.7818 | 0.4212 | 0.7203 | |
| SK-BR-3 | HER2amp | Luminal | Cetuximab | EGFR | ErbB | 0.0011 | uM | 7912.018 | 0.9867 | 0.9631 | 0.7203 | |
| SK-BR-3 | HER2amp | Luminal | Cetuximab | EGFR | ErbB | 0.00548 | uM | 7912.018 | 1.0116 | 1.0323 | 0.7203 | |
| SK-BR-3 | HER2amp | Luminal | Cetuximab | EGFR | ErbB | 0.0274 | uM | 7912.018 | 0.9591 | 0.8874 | 0.7203 | |
| SK-BR-3 | HER2amp | Luminal | Cetuximab | EGFR | ErbB | 0.137 | uM | 7912.018 | 0.8958 | 0.7166 | 0.7203 |